MiNK Therapeutics, Inc. (INKT )

Currency in USD Disclaimer
$12.03 +$4.17 (53.05%)
Closed 02/04/2025
$7.32
$13.61
$4.56
$19

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol INKT
  • Company MiNK Therapeutics, Inc.
  • Price $12.03
  • Changes Percentage 53.05
  • Change 4.17
  • Day Low $7.32
  • Day High $13.61
  • Year High $19
  • Year Low $4.56
  • Market Cap $47,578,614
  • Price Avg 50 EMA (D) $7.25
  • Price Avg 200 EMA (D) $8.2
  • Exchange NASDAQ
  • Volume 346,309
  • Average Volume 21,595
  • Open $7.95
  • Previous Close $7.86
  • EPS -3.7
  • PE -3.25
  • Earnings Announcement 2025-03-20 12:30:00
  • Shares Outstanding $3,954,997

Company brief: MINK THERAPEUTICS, INC. (INKT )

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

INKT Corporation News

Income Statement